已上市中成药说明书安全信息修订实践与思考

doi:10.19803/j.1672-8629.20240621

中国药物警戒 ›› 2025, Vol. 22 ›› Issue (2): 188-192.
DOI: 10.19803/j.1672-8629.20240621

已上市中成药说明书安全信息修订实践与思考

朱兰¹, 邵波¹, 朱彦², 戴洁³, 钟诗琦⁴

¹国家药品监督管理局药品评价中心,国家药品监督管理局药物警戒研究与评价重点实验室,北京 100076;
²中国中医科学院中医药信息研究所,北京 100700;
³陕西省药品不良反应监测中心,陕西西安 710065;
⁴贵州省药品评价中心,贵州贵阳 550081

收稿日期:2024-08-19 出版日期:2025-02-15 发布日期:2025-02-17
作者简介:朱兰,女,硕士,副主任药师,药品不良反应监测与评价。
基金资助:
国家自然科学基金资助项目(82174534); 中央级公益性科研院所基本科研业务费专项资金资助:中医药语义信息标准化探索研究(ZZ13-YQ-126)

Current Progress and Considerations in Updating the Safety Information in Labels of Chinese Traditional Patent Medicines

ZHU Lan¹, SHAO Bo¹, ZHU Yan², DAI Jie³, ZHONG Shiqi⁴

¹Center for Drug Reevaluation, NMPA/ NMPA Key Laboratory for Research and Evaluation of Pharmacovigilance, Beijing 100076, China;
²Institute of Information on Traditional Chinese Medicine, CACMS, Beijing 100700, China;
³Shaanxi Center for ADR Monitoring, Xi'an Shaanxi 710065, China;
⁴Center for Drug Reevaluation, Guiyang Guizhou 550081, China

Received:2024-08-19 Online:2025-02-15 Published:2025-02-17

摘要/Abstract

摘要： 目的总结已上市中成药说明书安全信息修订相关工作经验。方法梳理已上市中成药说明书【不良反应】【禁忌】【注意事项】和“警示语”修订相关指导原则及要求,结合实际工作提出针对性建议。结果由于历史原因,部分已上市中成药说明书存在安全信息缺失的情形,应该及时予以修订,使医务人员、患者及时全面了解药品安全信息,从而指导临床安全合理用药。结论说明书修订是药品风险管理措施之一,解决了说明书安全信息缺失的问题后,仍然需要持续开展不良反应监测、上市后研究与评价发现药品风险,通过修订说明书等措施控制药品风险。

关键词: 中药, 说明书, 安全性信息, 药品不良反应, 禁忌, 注意事项

Abstract: Objective To review Current status of updating safety information in labels of Chinese traditional patent medicines. Methods To analyze the guidelines and requirements for the updating of information on adverse reactions, contraindications, precautions and warnings information in the labels of Chinese traditional patent medicines, and to make suggestions based on working experience. Results For some historical reasons, safety information is missing from some Chinese traditional patent medicine labels and should be added to provide guidance to healthcare professionals and patients on the use of medicines. Conclusion Revision of labeling and updating of safety information is one of the risk management measures, after solving the problem of missing safety information, there is still a need for continuous monitoring of adverse reactions, post-marketing research to identify drug risks, and to control the risks by revising labels and other measures.

Key words: Chinese Traditional Medicine, Labels, Safety Information, Adverse Drug Reaction, Contraindications, Precautions

中图分类号:

朱兰, 邵波, 朱彦, 戴洁, 钟诗琦. 已上市中成药说明书安全信息修订实践与思考[J]. 中国药物警戒, 2025, 22(2): 188-192.

ZHU Lan, SHAO Bo, ZHU Yan, DAI Jie, ZHONG Shiqi. Current Progress and Considerations in Updating the Safety Information in Labels of Chinese Traditional Patent Medicines[J]. Chinese Journal of Pharmacovigilance, 2025, 22(2): 188-192.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://zgywjj.magtechjournal.com/CN/10.19803/j.1672-8629.20240621

https://zgywjj.magtechjournal.com/CN/Y2025/V22/I2/188

参考文献

[1] NMPA. NMPA Released a Guideline to Implement the Preservation and Innovative Development of Traditional Chinese Medicine(TCM)[EB/OL]. (2020-12-25)[2024-05-30]. https://www.nmpa.gov.cn/xxgk/fgwj/gzwj/gzwjyp/20201225163906151.html.
[2] NMPA. NMPA Released Special Provisions for TCM Registrations[EB/OL]. (2023-02-10)[2024-05-30]. https://www.nmpa.gov.cn/xxgk/ggtg/ypggtg/ypqtggtg/20230210173401120.html.
[3] State Administration for Market Regulation. Provisions for Drug Registration [EB/OL]. (2020-01-22)[2024-05-30]. https://www.samr.gov.cn/zw/zfxxgk/fdzdgknr/fgs/art/2023/art_3275cb2a929d4c34ac8c0421b2a9c257.html.
[4] NMPA. NMPA Announcement Application Requirements of Changing Marketed TCM[EB/OL]. (2021-02-24)[2024-05-30].https://www.nmpa.gov.cn/xxgk/fgwj/xzhgfxwj/20210224165613198.html.
[5] NMPA. NMPA Announcement on the Revision of the Package Insert of Xianlinggubao Capsules and Tablets[EB/OL]. (2017-01-09)[2024-05-30]. https://www.nmpa.gov.cn/xxgk/ggtg/ypggtg/ypqtggtg/20170111165801184.html.
[6] NMPA. NMPA Announcement on the Revision of the Package Insert of 4 Drugs Including Jingwu Capsule[EB/OL]. (2018-01-30)[2024-05-30]. https://www.nmpa.gov.cn/xxgk/ggtg/ypggtg/ypshmshxdgg/20180205170801445.html.
[7] NMPA. Announcement on the Conversion of Weitongning Tablets and Three Other Drugs into Prescription Drugs and Revision of the Package Inserts[EB/OL]. (2019-02-25)[2024-05-30]. https://www.nmpa.gov.cn/xxgk/ggtg/ypggtg/ypshmshxdgg/20190304104001392.html.
[8] NMPA. Regulations on Package Insert and Labeling of Drug[EB/OL]. (2006-03-15)[2024-05-30]. https://www.samr.gov.cn/zw/zfxxgk/fdzdgknr/bgt/art/2023/art_b1a64fa4b9314ecabadf3c6662b70c48.html.
[9] NMPA. NMPA Issues a Guideline for TCM and Natural Medicine Descriptions Instructions [R/OL]. (2006-06-22)[2024-05-30]. https://www.nmpa.gov.cn/xxgk/fgwj/gzwj/gzwjyp/20060622010101502.html.
[10] NMPA. NMPA Issues a Guideline for Labels of OTC Drugs[EB/OL]. (2006-10-20)[2024-05-30]. https://www.nmpa.gov.cn/directory/web/nmpa/xxgk/fgwj/gzwj/gzwjyp/20061020010101266.html.
[11] NMPA. NMPA Issues a Guideline for Updating Safety Information in Labels of TCM[R/OL]. (2022-01-04)[2024-05-30]. https://www.nmpa.gov.cn/yaopin/ypggtg/20220107145808154.html.
[12] NMPA. Good Pharmacovigilance Practices[R/OL]. (2021-05-07)[2024-05-30]. https://www.nmpa.gov.cn/xxgk/fgwj/xzhgfxwj/20210513151827179.html.
[13] NMPA. NMPA Announcement on Adopting ICH Level 2 Guidelines [R/OL]. (2018-01-25)[2024-05-30]. https://www.nmpa.gov.cn/xxgk/ggtg/ypggtg/ypqtggtg/20180125175101686.html.
[14] FU ZH, WANG L, MA PZ.Investigation and Analysis of Pregnancy Contraindication in Package Inserts of 273 Kinds of Chinese Patent Medicine[J]. Chinese Journal of Medicainal Guide(中国医药导刊), 2021, 23(5): 354.
[15] FU HT, CHENG Y, ZHANG QR.Investigation and Analysis of Pregnancy Contraindications and Pediatric Medication Information Labelling in 90 Kinds of Package Inserts of Chinese Patent Medicine90[J]. Herald of medicine(医药导报), 2021, 40(1): 109-114.
[16] NMPA. NMPA Announcement on the Revision of the Package Insert of Qingkailing and Yiqifumai Injections[R/OL]. (2018-06-18)[2024-09-25]. https://www.nmpa.gov.cn/xxgk/ggtg/ypggtg/ypshmshxdgg/20180703165601192.html.
[17] NMPA. NMPA Announcement on the Revision of the Package Insert of Qingkailing Oral Preparation[R/OL]. (2021-05-06)[2024-09-25]. https://www.nmpa.gov.cn/xxgk/ggtg/ypggtg/ypshmshxdgg/20210512104440187.html.
[18] ZHU Y, LI Q, ZHU L, et al.Current Situation and Suggestions Concerning the Implementation of MedDRA in Drug Monitoring in China[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2024, 21(7): 746-751.

已上市中成药说明书安全信息修订实践与思考

Current Progress and Considerations in Updating the Safety Information in Labels of Chinese Traditional Patent Medicines

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	李明颖, 张晓霞, 孙晓黎, 赵燕, 何苗, 李艳玲, 段薇, 杨鸥. 舒更葡糖钠对腹腔镜全盆底重建术后患者恢复的影响[J]. 中国药物警戒, 2025, 22(8): 896-901.
[2]	柯秀琴, 海学武. 433例羟苯磺酸钙胶囊不良反应分析[J]. 中国药物警戒, 2025, 22(8): 924-927.
[3]	梁洁. 172例抗肿瘤药品不良反应报告分析[J]. 中国药物警戒, 2025, 22(8): 928-932.
[4]	赵牡丹, 朱明辉, 张欢, 赵远洋, 秦靖. 1例彭氏变形杆菌致糖尿病足感染的药学监护[J]. 中国药物警戒, 2025, 22(8): 937-940.
[5]	周玗洁, 黄晓婧, 陈明月, 杜鹏强, 王爱凤. 注射用头孢哌酮舒巴坦钠致重度血小板减少2例分析[J]. 中国药物警戒, 2025, 22(8): 941-943.
[6]	陈桦宝, 刘薇, 蒋婷, 郑玲利, 李静. 盐酸纳洛酮注射液致急性戒断综合征1例分析[J]. 中国药物警戒, 2025, 22(8): 944-946.
[7]	杨欣, 杨宝春, 杨漾, 邵欢. 信迪利单抗致内分泌系统不良反应1例分析[J]. 中国药物警戒, 2025, 22(8): 947-949.
[8]	王春婷, 陈亚飞, 李婷婷. 化学药品上市后说明书安全信息修订考虑要点[J]. 中国药物警戒, 2025, 22(7): 776-779.
[9]	朱会卷, 任经天. 狂犬病人免疫球蛋白安全性风险分析[J]. 中国药物警戒, 2025, 22(7): 786-789.
[10]	陈耀哲, 詹云丽, 宋兴栋, 朱漫玉, 欧雪媚, 李楚云. 48例哌拉西林钠他唑巴坦钠血液系统不良反应分析[J]. 中国药物警戒, 2025, 22(7): 794-798.
[11]	曹凯, 钱佩佩, 高鑫, 杨付田, 赵亮, 徐炳欣, 张现军. 基于美国FAERS数据库的药物引起唾液腺结石不良事件信号分析[J]. 中国药物警戒, 2025, 22(7): 799-804.
[12]	林璐, 赵安职, 陈锦辉, 李忠文, 黄国华, 钟诗龙. 注射用头孢噻肟钠舒巴坦钠致迟发型超敏反应1例分析[J]. 中国药物警戒, 2025, 22(7): 809-811.
[13]	唐炯, 曾语琦. 舒格利单抗注射液致动眼神经麻痹1例分析[J]. 中国药物警戒, 2025, 22(7): 812-814.
[14]	王媛, 李若柠, 郭展立, 张磊, 李嘉媛, 冬颖, 孙建军. 替罗非班注射液致极重度血小板减少症1例分析[J]. 中国药物警戒, 2025, 22(7): 815-818.
[15]	雷建林, 王娜, 王文筝, 王岩. 复方妥英麻黄茶碱片致苯妥英钠中毒1例分析[J]. 中国药物警戒, 2025, 22(7): 819-822.